<DOC>
	<DOCNO>NCT00063414</DOCNO>
	<brief_summary>This multi-center trial test safety , efficacy tolerability alicaforsen ( ISIS 2302 ) , new type drug call antisense drug , patient mild moderate active Ulcerative Colitis ( UC ) . Alicaforsen design reduce production specific protein , call ICAM-1 , substance play significant role increase inflammation likely involved inflammatory bowel disease ulcerative colitis . The ISIS 2302-CS22 study examine effect one two dosage alicaforsen deliver enema six-week period compare active control , mesalamine enema ( The probability receive alicaforsen formulation 2:1 ) . The primary objective study evaluate percentage reduction DAI Week 6 .</brief_summary>
	<brief_title>ISIS 2302-CS22 , A 6-Week , Active-Controlled Clinical Study Evaluate Effectiveness Alicaforsen ( ISIS 2302 ) Patients With Mild Moderate Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Alicaforsen</mesh_term>
	<criteria>Inclusion criterion Patients must meet follow criterion screen eligible enrollment : Age great equal 18 year Diagnosis ulcerative colitis least 6 month duration Current leftsided flare , define activity colon 550 cm anal verge , extend least 15 cm proximal anal verge confirm endoscopic evaluation within 14 day baseline visit . Baseline DAI score 410 include abnormal endoscopic score On least one follow treatment ulcerative colitis prior baseline visit : 1 . Stable background oral mesalamine therapy great equal 30 day , and/or 2 . Stable background mercaptopurine great equal 60 day prior baseline , and/or 3 . Stable azathiprine therapy great equal 60 day prior baseline Written inform consent prior perform screen evaluation . Exclusion criteria Patients meet follow criterion screen eligible enrollment : Bowel stricture , toxic megacolon , colonic dysplasia , adenoma carcinoma Uncontrolled hematologic , renal , hepatic , metabolic , psychiatric , CNS , pulmonary cardiovascular disease , sufficient level disease could interfere patient 's ability comply protocol participation Enteric pathogens presence Clostridium difficile toxin stool History colon resection Major surgical procedure within one month baseline visit Steroid mesalamine enema within 14 day baseline visit Systemic steroid ( include ACTH ) within 30 day baseline visit Tumor necrosis factoralpha ( TNFÎ± ) inhibitor treatment within 90 day baseline visit Nonsteroidal antiinflammatory agent ( NSAIDs ) , include cyclooxygenase2 ( COX2 ) inhibitor , within 14 day baseline visit Methotrexate , cyclosporin thalidomide within 90 day baseline visit Any active infection currently require treatment Malignancy within 5 year except squamous cell basal cell cancer skin Current infectious , ischemic , immunological disease gastrointestinal involvement ISIS 2302 treatment within 12 month baseline visit History allergy mesalamine Treatment investigational offlabel drug within 90 day screen currently longterm follow another investigational treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>